COMBATING HOSPITAL ACQUIRED INFECTIONS THROUGH DISRUPTIVE TECHNOLOGIES

BUGWORKS is a drug discovery company that aims to discover novel biopharmaceutical assets for the treatment of Antimicrobial Resistance (AMR)

Who We are ?


A strong inter-disciplinary team with competencies in Entrepreneurship, Mathematics, Engineering, IT, Biochemistry, Microbiology, Molecular Biology, Pharmacology and Medicinal Chemistry.

What We Do ?


Towards treatment of AMR, we have unlocked a new paradigm that overcomes efflux mediated resistance, leading to the discovery of several novel chemical scaffolds effective against ESKAPE pathogens. Amalgamating systems biology with engineering principles, we are developing novel solutions to prevent and disrupt biofilms in device associated infections.

Why We Do ?


  • Centers for Disease Control (CDC) estimates that 1 in 25 patients worldwide will acquire an infection as a result of their hospital stay
  • 10 million deaths will occur worldwide if antibiotic resistance is left unchecked, costing the world $100 trillion by 2050
  • The antibiotic pipeline lack new mechanisms against drug resistant Gram negative bacteria